Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: Patient global health is a confounder

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Balogh, Emese ^a,b   Dias, Joao M ^a   Orr, Carl ^a   Mullan, Ronan ^a   Harty, Len ^a   FitzGerald, Oliver ^a   Gallagher, Phil ^a   Molloy, Miriam ^a   O'Flynn, Eileen ^a   Kelly, Alexia ^a   Minnock, Patricia ^a   O'Neill, Madeline ^a   Moore, Louise ^a   Murray, Mairead ^a   Fearon, Ursula ^a   Veale, Douglas J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG ANTAGONISM; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CHILD; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84890818397     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4421     Document Type: Article

References (30)

1. Roll P, Muhammad K, Schumann M, Kleinert S, Tony HP. RF positivity has substantial influence on the peripheral memory B-cell compartment and its modulation by TNF inhibition. Scand J Rheumatol 2012, 41:180-185. 10.3109/03009742.2011.645056, 22400711.
2. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS)28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007, 66:407-409. 10.1136/ard.2006.054205, 1856019, 16926186.
3. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005, 23:S93-S99.
4. Fransen J, Welsing PM, de Keijzer RM, et al. Disease activity scores using C-reactive protein: CRP may replace ESR in the assessment of RA disease activity. Ann Rheum Dis 2004, 62:151.
5. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174. 10.2307/2529310, 843571.
6. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'Dell JR, Kazi S. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012, 64:640-647. 10.1002/acr.21649, 22473918.
7. Prince FH, Bykerk VP, Shadick NA, Lu B, Cui J, Frits M, Iannaccone CK, Weinblatt ME, Solomon DH. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther 2012, 14:R68. 10.1186/ar3785, 3446437, 22429277.
8. Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, Burmester G, Combe B, Cutolo M, Dougados M, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2011, 69:638-643.
9. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637. 10.1136/ard.2009.123919, 3015099, 20215140.
10. Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, Iannaccone CK, Kvien TK, Haavardsholm EA, Weinblatt ME, et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012, 71:681-686. 10.1136/ard.2011.154625, 21994234.
11. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011, 70:404-413. 10.1136/ard.2011.149765, 21292833.
12. Vermeer M, Kuper HH, van der Bijl AE, Baan H, Posthumus MD, Brus HL, van Riel PL, van de Laar MA. The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. Rheumatology (Oxford) 2012, 51:1076-1080. 10.1093/rheumatology/ker425, 22302059.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
14. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850. 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K, 9778226.
15. van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, Herrero-Beaumont G, Molad Y, Codreanu C, Valentini G, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:3928-3939. 10.1002/art.23141, 18050208.
16. Vrijhoef HJ, Diederiks JP, Spreeuwenberg C, Van der Linden S. Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:419-422. 10.1136/ard.62.5.419, 1754526, 12695152.
17. Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis 2012, 71:1702-1705. 10.1136/annrheumdis-2012-201519, 22736085.
18. Firth J. Rheumatoid arthritis: treating to target with disease-modifying drugs. Br J Nurs 2011, 20:1244-1245. 1240, 1242.
19. Firth J, Critchley S. Treating to target in rheumatoid arthritis: biologic therapies. Br J Nurs 2011, 20:1284-1288. 1287-1288, 1290-1281.
20. Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken) 2011, 63:S14-S36. 10.1002/acr.20621, 22588741.
21. Bazzichi L, Rossi P, Giacomelli C, De Feo F, Bobbio-Pallavicini F, Rossi A, Baldini C, Consensi A, Doveri M, Bonino C, et al. A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis. Rheumatol Int 2012, 32:349-356. 10.1007/s00296-010-1619-7, 21110028.
22. Makinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol 2006, 24:S-22-S-28.
23. de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA, van Riel PL. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) 2012, 51:1610-1617. 10.1093/rheumatology/kes078, 22539487.
24. Hirabayashi Y, Ishii T. The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab. Clin Rheumatol 2013, 32:123-127. 10.1007/s10067-012-2103-4, 3558670, 23090655.
25. Masri KR, Shaver TS, Shahouri SH, Wang S, Anderson JD, Busch RE, Michaud K, Mikuls TR, Caplan L, Wolfe F. Validity and reliability problems with patient global as a component of the ACR/EULAR remission criteria as used in clinical practice. J Rheumatol 2012, 39:1139-1145. 10.3899/jrheum.111543, 22589262.
26. Ma MH, Ibrahim F, Walker D, Hassell A, Choy EH, Kiely PD, Williams R, Walsh DA, Young A, Scott DL. Remission in early rheumatoid arthritis: predicting treatment response. J Rheumatol 2012, 39:470-475. 10.3899/jrheum.110169, 22247360.
27. van der Heijde D. Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?. Ann Rheum Dis 2012, 71:i89-i92. 10.1136/annrheumdis-2011-200797, 22460147.
28. Zhang B, Combe B, Rincheval N, Felson DT. Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort. Arthritis Res Ther 2012, 14:R156. 10.1186/ar3896, 3446542, 22747951.
29. Sakellariou G, Scire CA, Verstappen SM, Montecucco C, Caporali R. In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Ann Rheum Dis 2012, 72:245-249.
30. Bykerk VP, Keystone EC, Kuriya B, Larché M, Thorne JC, Haraoui B. Achieving remission in clinical practice: lessons from clinical trial data. Clin Exp Rheumatol 2013, 31:621-632.